NYX-783

DRUG3 trials

Sponsors

Aptinyx, Yale University

Conditions

Opioid Use DisorderPTSDPost-Traumatic Stress Disorder

Phase 1

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

CompletedNCT05447286

Yale UniversityOpioid Use Disorder

Start: 2023-05-15End: 2024-12-30Updated: 2025-03-25

Phase 2

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

CompletedNCT04044664

AptinyxPost-Traumatic Stress Disorder

Start: 2019-01-25End: 2020-08-05Updated: 2022-05-17

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

TerminatedNCT05181995

Start: 2021-12-13End: 2023-03-30Updated: 2023-04-07